Suppr超能文献

八种喹诺酮类药物对脆弱拟杆菌群成员的比较活性

Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

作者信息

Borobio M V, Conejo M, Ramirez E, Suarez A I, Perea E J

机构信息

Department of Microbiology, University of Seville.

出版信息

Antimicrob Agents Chemother. 1994 Jun;38(6):1442-5. doi: 10.1128/AAC.38.6.1442.

DOI:10.1128/AAC.38.6.1442
PMID:8092852
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC188229/
Abstract

The in vitro activities of five new quinolones (clinafloxacin [CI-960 or PD-127391], BAY Y 3118, E-4868, E-5065, and E-5068) against 100 Bacteroides fragilis group bacterial isolates were compared with those of ciprofloxacin, ofloxacin, and sparfloxacin. Overall, E-5068 was the most active in vitro (MIC for 90% of isolates tested [MIC90], 0.25 microgram/ml); this was followed by clinafloxacin and BAY Y 3118 (MIC90, 0.5 microgram/ml). Ciprofloxacin, sparfloxacin, and ofloxacin were the least active (MIC90s, 64, 16, and 16 micrograms/ml, respectively). B. fragilis and Bacteroides caccae were more susceptible than the other members of the B. fragilis group to all of the quinolones tested.

摘要

比较了五种新型喹诺酮类药物（克林沙星[CI-960或PD-127391]、BAY Y 3118、E-4868、E-5065和E-5068）对100株脆弱拟杆菌属细菌分离株的体外活性，并与环丙沙星、氧氟沙星和司帕沙星进行了比较。总体而言，E-5068的体外活性最强（90%受试分离株的最低抑菌浓度[MIC90]为0.25微克/毫升）；其次是克林沙星和BAY Y 3118（MIC90为0.5微克/毫升）。环丙沙星、司帕沙星和氧氟沙星的活性最低（MIC90分别为64、16和16微克/毫升）。脆弱拟杆菌和粪拟杆菌比脆弱拟杆菌属的其他成员对所有测试的喹诺酮类药物更敏感。

相似文献

1
Comparative activities of eight quinolones against members of the Bacteroides fragilis group.
Antimicrob Agents Chemother. 1994 Jun;38(6):1442-5. doi: 10.1128/AAC.38.6.1442.
2
Comparative in vitro activities of new quinolones against coryneform bacteria.
Antimicrob Agents Chemother. 1994 Jun;38(6):1439-41. doi: 10.1128/AAC.38.6.1439.
3
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Antimicrob Agents Chemother. 1992 May;36(5):1158-62. doi: 10.1128/AAC.36.5.1158.
4
In-vitro activity of four new fluoroquinolones.
J Antimicrob Chemother. 1994 Jul;34(1):53-64. doi: 10.1093/jac/34.1.53.
5
Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. doi: 10.1128/AAC.38.2.369.
6
In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):319-30. doi: 10.1016/0732-8893(91)90023-9.
7
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5. doi: 10.1128/AAC.43.9.2251.
8
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Antimicrob Agents Chemother. 2001 Jul;45(7):1977-81. doi: 10.1128/AAC.45.7.1977-1981.2001.
9
In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
Antimicrob Agents Chemother. 1993 May;37(5):997-1000. doi: 10.1128/AAC.37.5.997.
10
In vitro activity of BAY 12-8039, a new fluoroquinolone.
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6. doi: 10.1128/AAC.41.1.101.

引用本文的文献

1
Common Oral Medications Lead to Prophage Induction in Bacterial Isolates from the Human Gut.
Viruses. 2021 Mar 11;13(3):455. doi: 10.3390/v13030455.
2
In vitro activities of newer quinolones against bacteroides group organisms.
Antimicrob Agents Chemother. 2002 Oct;46(10):3276-9. doi: 10.1128/AAC.46.10.3276-3279.2002.
3
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5. doi: 10.1128/AAC.43.9.2251.
4
Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.
Infection. 1999 May-Jun;27(3):166-72. doi: 10.1007/BF02561522.
5
In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.
Antimicrob Agents Chemother. 1998 Feb;42(2):419-24. doi: 10.1128/AAC.42.2.419.

本文引用的文献

1
Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
J Antimicrob Chemother. 1993 Jun;31(6):893-900. doi: 10.1093/jac/31.6.893.
2
In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.
Eur J Clin Microbiol Infect Dis. 1993 Feb;12(2):134-41. doi: 10.1007/BF01967592.
3
In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Eur J Clin Microbiol Infect Dis. 1993 Aug;12(8):640-2. doi: 10.1007/BF01973648.
4
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
J Antimicrob Chemother. 1993 Apr;31(4):505-22. doi: 10.1093/jac/31.4.505.
5
Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.
Antimicrob Agents Chemother. 1984 Mar;25(3):342-3. doi: 10.1128/AAC.25.3.342.
6
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
Antimicrob Agents Chemother. 1980 Feb;17(2):103-8. doi: 10.1128/AAC.17.2.103.
7
Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.
Antimicrob Agents Chemother. 1985 Apr;27(4):657-9. doi: 10.1128/AAC.27.4.657.
8
Symposium on antimicrobial agents. The quinolones.
Mayo Clin Proc. 1987 Nov;62(11):1007-12. doi: 10.1016/s0025-6196(12)65073-3.
9
The in-vitro activity of PD127,391, a new quinolone.
J Antimicrob Chemother. 1988 Aug;22(2):135-41. doi: 10.1093/jac/22.2.135.
10
Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.
Rev Infect Dis. 1990 Jan-Feb;12 Suppl 2:S142-51. doi: 10.1093/clinids/12.supplement_2.s142.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验